Femicare
- Address
- Gasthuismolenstraat 33, 3300 Tienen, Belgium
Bacterial Infections and Mycoses
At Femicare in Tienen, the clinical research in this area focuses on recurrent vulvovaginal candidiasis, a common and often recurring fungal infection affecting women. The studies are designed to explore better ways to prevent recurrence, strengthen immune protection, and improve overall management of this condition.
- Evaluating a Candida vaccine as a potential new approach for reducing repeated infections
- Studying immune response and early signs of effectiveness in women with recurrent disease
This work supports the development of more effective options for a condition that can be difficult to control with standard care.
Female Urogenital Diseases and Pregnancy Complications
Research in this therapeutic area centers on vasomotor symptoms, especially hot flashes linked to adjuvant endocrine therapy in women with, or at high risk for, hormone-receptor positive breast cancer. The trials aim to improve symptom relief and help patients tolerate cancer treatment more comfortably.
- Testing a new therapy for managing treatment-related hot flashes and related discomfort
- Assessing how well the approach works and how safe it is compared with placebo
These studies reflect a strong interest in supportive care for women undergoing cancer-related treatment, with attention to both symptom control and quality of life.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Femicare
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Elinzanetant in Treating Vasomotor Symptoms Induced by Adjuvant Endocrine Therapy in Hormone-Receptor Positive Breast Cancer Patients | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2022 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Elinzanetant | 1 | Unknown | 2022-10-13 | 2022-10-13 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.